一品红(300723.SZ)：全资子公司芩香清解口服液获得药物临床试验通知书

Core Viewpoint - Yipinhong (300723.SZ) has received approval from the National Medical Products Administration for clinical trials of its product, Qinxiang Qingjie Oral Liquid, aimed at treating acute upper respiratory infections in adults [1] Group 1: Company Developments - Yipinhong's wholly-owned subsidiary, Yipinhong Biopharmaceutical Co., Ltd., has submitted an application for Qinxiang Qingjie Oral Liquid, which has now been accepted for clinical trials [1] - The approval notification number for the clinical trial is 2026LP00262, indicating formal recognition by regulatory authorities [1] Group 2: Industry Context - The clinical trial is focused on a specific indication, namely acute upper respiratory infections with both heat syndrome, highlighting the company's targeted approach in the biopharmaceutical sector [1]